Skip to Content
Merck
All Photos(1)

Documents

SML3110

Sigma-Aldrich

CRANAD-3

≥98% (HPLC)

Synonym(s):

(T-4)-[(1E,6E)-1,7-Bis[6-(diethylamino)-3-pyridinyl]-1,6-heptadiene-3,5-dionato-κO3,κO5]difluoroboron, CRANAD 3

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H31BF2N4O2
CAS Number:
1561983-97-8
Molecular Weight:
468.35
UNSPSC Code:
12352202
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

gray to black

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

FB(O1)(F)O=C(/C=C/C2=CN=C(N(CC)CC)C=C2)C=C1/C=C/C3=CC=C(N(CC)CC)N=C3

Biochem/physiol Actions

CRANAD-3, a curcumin analog, is a brain barrier penetrant smart NIRF (near-infrared) probe for both soluble and insoluble Aβ (amyloid beta) species in vivo. CRANAD-3 could be used to monitor the decrease in Aβs after drug treatment in transgenic AD (APP/PS1) mice. CRANAD-3 is suitable for in vivo dually-amplify signal via chemiluminescence resonance energy transfer (DAS-CRET) with ADLumin-1 a brain blood barrier penetrant smart chemiluminescence probe for Aβs

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Congping Chen et al.
ACS chemical neuroscience, 9(12), 3128-3136 (2018-08-02)
Abnormal deposition of brain amyloid is a major hallmark of Alzheimer's disease (AD). The toxic extracellular amyloid plaques originating from the aberrant aggregation of beta-amyloid (Aβ) protein are considered to be the major cause of clinical deficits such as memory
Xueli Zhang et al.
Proceedings of the National Academy of Sciences of the United States of America, 112(31), 9734-9739 (2015-07-23)
Near-infrared fluorescence (NIRF) molecular imaging has been widely applied to monitoring therapy of cancer and other diseases in preclinical studies; however, this technology has not been applied successfully to monitoring therapy for Alzheimer's disease (AD). Although several NIRF probes for
Jing Yang et al.
Nature communications, 11(1), 4052-4052 (2020-08-15)
Turn-on fluorescence imaging is routinely studied; however, turn-on chemiluminescence has been rarely explored for in vivo imaging. Herein, we report the design and validation of chemiluminescence probe ADLumin-1 as a turn-on probe for amyloid beta (Aβ) species. Two-photon imaging indicates

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service